ABSTRACT
Over the past decade, the development of ICI (immune checkpoint inhibitors) has constituted a revolution in the treatment of many cancers, but with a specific toxicity profile including endocrine IRAEs (immune-related adverse events). As the indications for these molecules are constantly increasing due to their efficacy, it is important that endocrinologists and oncologists know how to detect, manage and monitor this type of toxicity. Many guidelines and recommendations have been proposed in the last few years for the management of endocrinopathies. French guidelines on immunotherapy-related endocrine IRAEs were published in 2018, with a specific algorithm for hypophysitis and primary adrenal insufficiency (PAI), based on clinical suspicion followed by biochemical and imaging evaluation, and are still relevant today. Here we present the general pathophysiological mechanisms of these toxicities, and discuss the incidence, diagnosis, treatment, progression, management and monitoring of pituitary and adrenal disorders in patients treated by immunotherapy, with emphasis on hypophysitis, which is much more frequent than PAI with this type of molecule. We also highlight several key points, such as the need for emergency treatment by hydrocortisone with the possibility of continuing immunotherapy in these endocrinopathies, and the long-term persistence of corticotropin or adrenal deficiency in most cases, requiring specific "hydrocortisone education". These points should be kept in mind by oncologists and endocrinologists who treat and monitor patients treated by immunotherapy.
Subject(s)
Adrenal Gland Diseases , Endocrine System Diseases , Hypophysitis , Neoplasms , Humans , Immune Checkpoint Inhibitors/adverse effects , Hydrocortisone/adverse effects , CTLA-4 Antigen , Endocrine System Diseases/chemically induced , Endocrine System Diseases/therapy , Adrenal Gland Diseases/chemically induced , Adrenal Gland Diseases/diagnosis , Adrenal Gland Diseases/therapy , Neoplasms/drug therapy , Neoplasms/complications , Hypophysitis/chemically induced , Hypophysitis/therapyABSTRACT
A 68-year-old woman was admitted to the hospital for elective total knee arthroplasty in both knees without preceding heparin exposure. She developed adrenal haemorrhage and thrombocytopaenia on postoperative day 12, followed by right leg arterial occlusion and multiple venous intra-abdominal sites thrombosis. After given unfractionated heparin to treat arterial occlusion, platelet count was gradually declined. Spontaneous heparin-induced thrombocytopaenia was diagnosed by heparin-induced platelet activation test with light transmission aggregometry. The patient was successfully treated with fondaparinux and intravenous immunoglobulin. Apixaban was given after recovery of platelet count. Resolution of both thrombus along aorta and adrenal haemorrhage were shown by CT of whole abdomen after 2 months of treatment. Our case demonstrates that this serious complication is important but seldom recognised early.
Subject(s)
Adrenal Gland Diseases , Arthroplasty, Replacement, Knee , Thrombocytopenia , Adrenal Gland Diseases/chemically induced , Aged , Anticoagulants/adverse effects , Arthroplasty, Replacement, Knee/adverse effects , Female , Hemorrhage , Heparin/adverse effects , Humans , Thrombocytopenia/chemically induced , Thrombocytopenia/drug therapySubject(s)
Antineoplastic Agents, Immunological/therapeutic use , Kidney Failure, Chronic/therapy , Neoplasms/drug therapy , Renal Dialysis , Adrenal Gland Diseases/chemically induced , Aged , Aged, 80 and over , B7-H1 Antigen/antagonists & inhibitors , CTLA-4 Antigen/antagonists & inhibitors , Carcinoma, Merkel Cell/complications , Carcinoma, Merkel Cell/drug therapy , Female , Head and Neck Neoplasms/complications , Head and Neck Neoplasms/drug therapy , Humans , Hypothyroidism/chemically induced , Kidney Failure, Chronic/complications , Lung Neoplasms/complications , Lung Neoplasms/drug therapy , Male , Melanoma/complications , Melanoma/drug therapy , Middle Aged , Myocarditis/chemically induced , Myositis/chemically induced , Neoplasms/complications , Pneumonia/chemically induced , Programmed Cell Death 1 Receptor/antagonists & inhibitors , Retrospective Studies , Skin Neoplasms/complications , Skin Neoplasms/drug therapy , Treatment Outcome , Urogenital Neoplasms/complications , Urogenital Neoplasms/drug therapyABSTRACT
This study aims to examine the co-occurrence rate of attention deficit hyperactivity disorder (ADHD) and adrenal gland disorders, as well as whether pharmacotherapy may affect ADHD patients' risk of developing adrenal gland disorder. One group of patients newly diagnosed with ADHD (n = 75,247) and one group of age- and gender-matching controls (n = 75,247) were chosen from Taiwan's National Health Insurance database during the period of January 1999 to December 2011. Both patients and controls were monitored through December 31, 2011, in order to identify the occurrence of adrenal gland disorders (ICD-9-CM code 255.X). We also explored the potential effect of methylphenidate (MPH) and atomoxetine (ATX) treatments on the risk of developing adrenal gland disorders. We found that ADHD patients showed a significantly increased probability of developing an adrenal gland disorder compared to the control group (0.2% of ADHD vs. 0.1% of controls). However, neither MPH nor ATX treatment significantly influenced the patients' risk of developing adrenal gland dysfunction. We propose that patients with ADHD had greater comorbid rates with adrenal gland dysfunction than the control subjects. Nevertheless, undergoing treatment with MPH or ATX did not significantly influence the risk of developing adrenal gland dysfunction among ADHD patients.
Subject(s)
Adrenal Gland Diseases , Attention Deficit Disorder with Hyperactivity , Central Nervous System Stimulants , Adrenal Gland Diseases/chemically induced , Adrenal Glands/drug effects , Attention Deficit Disorder with Hyperactivity/drug therapy , Central Nervous System Stimulants/adverse effects , Central Nervous System Stimulants/therapeutic use , Child, Preschool , Female , Humans , Male , TaiwanABSTRACT
Immune checkpoint inhibitors (ICPIs) are novel drugs in the field of oncology however carry the risk of immune-related dermatologic, gastrointestinal, and endocrine side effects which can be fatal. These new innovative immunoregulatory drugs have intertwined the fields of oncology and endocrinology. CTLA-4 and PD-1 are co-inhibitory receptors on T cells that turn the T cell 'off' when binding to receptors on APCs. Tumor cells can also carry receptors for CTLA- and PD-1. By rendering T cells inactive, tumor cells can evade immune attack. Antibodies that bind to CTLA-4 and PD-1 lead to T cell activation and destruction of both tumor and normal host cells. ICPIs have been used in a variety of malignancies including melanoma, kidney cancer, and non-small cell lung cancer. A unique underrecognized side effect of the autoimmune response is hypophysitis leading to central adrenal insufficiency which can be fatal. Additional immune-related adverse events (irAEs) include hypothyroidism, hyperthyroidism, diabetes, and hypoparathyroidism.
Subject(s)
Antineoplastic Agents, Immunological/adverse effects , CTLA-4 Antigen/antagonists & inhibitors , Endocrine System Diseases/chemically induced , Immunotherapy/adverse effects , Programmed Cell Death 1 Receptor/antagonists & inhibitors , Adrenal Gland Diseases/chemically induced , Antineoplastic Agents, Immunological/immunology , Antineoplastic Agents, Immunological/pharmacology , CTLA-4 Antigen/immunology , Diabetes Mellitus, Type 1/chemically induced , Endocrine System Diseases/physiopathology , Humans , Hypophysitis/chemically induced , Immunotherapy/methods , Neoplasms/drug therapy , Programmed Cell Death 1 Receptor/immunology , Severity of Illness Index , T-Lymphocytes/immunology , Thyroid Diseases/chemically inducedABSTRACT
INTRODUCTION: Adrenal hemorrhage is a classical but rare complication of antiphospholipid syndrome, revealing diagnosis in one third of the cases. Anti-vitamin K therapy is the standard treatment but direct oral anticoagulants are discussed as an alternative. In the latest recommendations, it is advised not to use direct oral anticoagulants in the setting of antiphospholipid syndrome. CASE REPORT: We present a case of bilateral adrenal hemorrhage revealing primary antiphospholipid syndrome with triple positive antibody profile, in a 47-year-old man treated by apixaban for previous venous thromboembolism. CONCLUSION: To our knowledge, it is the first case of adrenal hemorrhage occurring during apixaban treatment in a patient with antiphospholipid syndrome. This case illustrates the inefficacy of direct oral anticoagulants to prevent thrombotic events in antiphospholipid syndrome, in accordance with the latest recommendations.
Subject(s)
Adrenal Gland Diseases/chemically induced , Antiphospholipid Syndrome/diagnosis , Hemorrhage/chemically induced , Pyrazoles/adverse effects , Pyridones/adverse effects , Adrenal Gland Diseases/diagnosis , Adrenal Glands/drug effects , Adrenal Glands/pathology , Antiphospholipid Syndrome/complications , Hemorrhage/diagnosis , Humans , Male , Middle Aged , Necrosis/chemically induced , Necrosis/diagnosis , Pyrazoles/therapeutic use , Pyridones/therapeutic use , Venous Thromboembolism/complications , Venous Thromboembolism/drug therapyABSTRACT
Spontaneous unilateral adrenal haemorrhage (AH) is extremely rare. Its presentation is usually non-specific and requires a high degree of suspicion as it is associated with high morbidity and mortality if diagnosis is delayed. Hereby, we present a case of 67-year-old man with significant cardiac history presented with right-sided chest pain and non-specific abdominal pain. He was previously treated for non-ST elevation myocardial infarction 5 days ago prior to the current presentation. CT scan of abdomen and pelvis demonstrated a right-sided active AH. The patient subsequently underwent digital subtraction angiography. Angio-embolisation was attempted for the pseudoaneurysm but failed due to spasm of the vessel. He was managed conservatively and discharged after clinical improvement. Clinic review 6 months later showed significant size reduction of the pseudoaneurysm.
Subject(s)
Adrenal Gland Diseases/chemically induced , Aneurysm, False/chemically induced , Anticoagulants/adverse effects , Chest Pain/diagnostic imaging , Hemorrhage/chemically induced , Non-ST Elevated Myocardial Infarction/drug therapy , Abdominal Pain/chemically induced , Abdominal Pain/diagnostic imaging , Adrenal Gland Diseases/diagnostic imaging , Aged , Aneurysm, False/diagnostic imaging , Angiography, Digital Subtraction , Anticoagulants/therapeutic use , Chest Pain/chemically induced , Conservative Treatment , Hemorrhage/diagnostic imaging , Humans , Male , Non-ST Elevated Myocardial Infarction/physiopathology , Tomography, X-Ray Computed , Treatment OutcomeABSTRACT
BACKGROUND Marijuana is the considered the most widely available and used drug across the world. Up to this time, there have been no reports of human death directly caused by acute marijuana toxicity in adults, fetuses, or newborn neonates. CASE REPORT We report a death of an 11-day-old white female neonate due to acute marijuana toxicity. She died of extensive necrosis and hemorrhage of the liver and adrenals due to maternal use of marijuana. CONCLUSIONS This case is unique in that other possible causes of death can be eliminated. With growing use of marijuana by pregnant women and increases in newborn drug screening of umbilical cord homogenate, more cases of neonatal death due to acute marijuana toxicity could be discovered.
Subject(s)
Adrenal Gland Diseases/chemically induced , Cannabis/adverse effects , Chemical and Drug Induced Liver Injury , Perinatal Death/etiology , Prenatal Exposure Delayed Effects/chemically induced , Fatal Outcome , Female , Humans , Infant, Newborn , PregnancySubject(s)
Adrenal Gland Diseases/chemically induced , Anticoagulants/adverse effects , Atrial Fibrillation/chemically induced , Diabetic Angiopathies/complications , Heparin/adverse effects , Non-ST Elevated Myocardial Infarction/drug therapy , Vasoconstrictor Agents/therapeutic use , Adrenal Gland Diseases/drug therapy , Aged , Anticoagulants/administration & dosage , Atrial Fibrillation/drug therapy , Diabetic Angiopathies/physiopathology , Hemorrhage/chemically induced , Heparin/administration & dosage , Hirudins/administration & dosage , Hirudins/adverse effects , Humans , Hydrocortisone , Hypotension/chemically induced , Male , Non-ST Elevated Myocardial Infarction/diagnosis , Peptide Fragments/administration & dosage , Peptide Fragments/adverse effects , Recombinant Proteins/administration & dosage , Recombinant Proteins/adverse effects , Thrombocytopenia/chemically induced , Thrombocytopenia/drug therapy , Treatment OutcomeABSTRACT
BACKGROUND: Ataxia telangiectasia is an autosomal recessive disorder characterized by cerebellar ataxia, telangiectases, immune defects, and a predisposition to malignancy. Quality of life is severely impaired by neurological symptoms. However, curative options for the neurological symptoms are limited. Recent studies have demonstrated short-term improvement in neurological symptoms with betamethasone therapy. However, the long-term and adverse effects of betamethasone are unclear. The aim of this study was to evaluate the long-term effects, benefits, and adverse effects of low-dose betamethasone in ataxia telangiectasia. METHODS: Six patients with ataxia telangiectasia received betamethasone at 0.02 mg/kg/day for two years. After cessation of betamethasone, the patients were observed for two additional years. Neurological assessments were performed, and adverse effects were monitored every three months throughout the four-year study period. RESULTS: Transient improvement of neurological symptom was observed in five of the six patients. However, after two years betamethasone treatment, only one of the six patients showed a slight improvement in the neurological score, one patient showed no change, and the neurological scores of the remaining four patients deteriorated. After the cessation of betamethasone treatment, neurological symptoms worsened in all patients. As an adverse effect of betamethasone, transient adrenal dysfunction was observed in all cases. CONCLUSIONS: Although these findings are in agreement with previous studies suggesting that short-term betamethasone treatment transiently benefits patients with ataxia telangiectasia, the long-term benefits and risks should be carefully considered.
Subject(s)
Ataxia Telangiectasia/drug therapy , Betamethasone/pharmacology , Drug-Related Side Effects and Adverse Reactions , Glucocorticoids/pharmacology , Outcome Assessment, Health Care , Adolescent , Adrenal Gland Diseases/chemically induced , Betamethasone/administration & dosage , Betamethasone/adverse effects , Child , Female , Glucocorticoids/administration & dosage , Glucocorticoids/adverse effects , Humans , Longitudinal Studies , Male , Peripheral Nervous System Diseases/chemically inducedABSTRACT
Immune checkpoint inhibitors (ICIs) have become a promising treatment for advanced malignancies. However, these drugs can induce immune-related adverse events (irAEs) in several organs, including skin, gastrointestinal tract, liver, muscle, nerve, and endocrine organs. Endocrine irAEs comprise hypopituitarism, primary adrenal insufficiency, thyroid dysfunction, hypoparathyroidism, and type 1 diabetes mellitus. These conditions have the potential to lead to life-threatening consequences, such as adrenal crisis, thyroid storm, severe hypocalcemia, and diabetic ketoacidosis. It is therefore important that both endocrinologists and oncologists understand the clinical features of each endocrine irAE to manage them appropriately. This opinion paper provides the guidelines of the Japan Endocrine Society and in part the Japan Diabetes Society for the management of endocrine irAEs induced by ICIs.
Subject(s)
Endocrine System Diseases/chemically induced , Endocrine System Diseases/therapy , Immune System Diseases/chemically induced , Immune System Diseases/therapy , Immunologic Factors/adverse effects , Protein Kinase Inhibitors/adverse effects , Adrenal Gland Diseases/chemically induced , Adrenal Gland Diseases/therapy , Antibodies, Monoclonal/adverse effects , Antibodies, Monoclonal/therapeutic use , Cell Cycle Checkpoints/drug effects , Cell Cycle Checkpoints/immunology , Diabetes Mellitus/chemically induced , Diabetes Mellitus/immunology , Diabetes Mellitus/therapy , Endocrine System Diseases/diagnosis , Humans , Immune System Diseases/diagnosis , Immunologic Factors/therapeutic use , Japan , Parathyroid Diseases/chemically induced , Parathyroid Diseases/therapy , Protein Kinase Inhibitors/therapeutic use , Societies, Medical/organization & administration , Societies, Medical/standards , Thyroid Diseases/chemically induced , Thyroid Diseases/therapyABSTRACT
Clinical and pathological case files of lethal snakebites were reviewed from the Magway Region General Hospital, Magway, Myanmar, over a five-year period (January 2013 December 2017). A total of 2069 postmortem examinations were performed which included 84 cases of lethal snake bite (4.1%). The annual numbers ranged from 10 out of a total of 268 autopsies in 2013 (3.7%), to 31 out of a total of 501 autopsies in 2016 (6.2%). There were 54 males (64%) and 30 females (36%) (M:Fâ¯=â¯1.9:1; age range 5-75yrs, mean 33yrs). The most common time for lethal envenomation was August (16/84-19%), the middle of the monsoon season. 45/84 (54%) had acute renal failure, 27/84 (32%) were shocked, and the remaining 12/84 (14%) had disseminated intravascular coagulation. Twenty cases (24%) died within 24â¯h after envenomation. Fang marks were identified on the legs (either right or left) in 73/84 cases (87%) and on the arms in five cases (6%). The predominant findings at autopsy were of acute renal injury (82/84-98%), pituitary haemorrhage/necrosis (36/84-43%), and adrenal gland haemorrhage (30/84-36%). Despite the reduction in fatalities over the years snakebite from Russell's viper in particular remains an important contributor to mortality in central Myanmar despite the availability of antivenom.
Subject(s)
Snake Bites/mortality , Snake Venoms/poisoning , Acute Kidney Injury/chemically induced , Acute Kidney Injury/mortality , Adolescent , Adrenal Gland Diseases/chemically induced , Adrenal Gland Diseases/mortality , Adult , Age Distribution , Aged , Animals , Child , Child, Preschool , Disseminated Intravascular Coagulation/chemically induced , Disseminated Intravascular Coagulation/mortality , Female , Hemorrhage/chemically induced , Hemorrhage/mortality , Humans , Male , Middle Aged , Myanmar/epidemiology , Necrosis , Pituitary Diseases/chemically induced , Pituitary Diseases/mortality , Pituitary Gland/pathology , Retrospective Studies , Sex Distribution , Shock/chemically induced , Shock/mortality , Young AdultABSTRACT
Glucocorticoids play a major factor in fetal maturation and fate decision after birth. We have previously demonstrated that prenatal caffeine exposure (PCE) resulted in adrenal dysplasia. However, its molecular mechanism has not been clarified. In the present study, a rat model of intrauterine growth retardation (IUGR) was established by PCE, and offspring were sacrificed. Moreover, NCI-H295 A cells were used to confirm glucocorticoid-related molecular mechanism. Results showed that PCE fetal weight decreased, and the IUGR rate increased, while serum corticosterone levels increased but insulin-like growth factor 1 (IGF1) levels decreased. Fetal adrenals exhibited an activated glucocorticoid-activation system, and the downregulated expression of IGF1 signal pathway and steroidal synthetases. For adult rats, there was no significant change in the glucocorticoid-activation system in the PCE group, the IGF1 signal pathway showed increased trend, and the expression levels of adrenal steroidal synthetases were close to normal. The data in vitro showed that the cortisol of 1200 nM can inhibit the expression of adrenocortical cell steroidal synthetases and IGF1 signal pathway when compared with the control. Meanwhile, the glucocorticoid-activation system was activated while GR inhibitor mifepristone can reverse the effect of cortisol. Furthermore, cortisol can also promote GR into the nucleus after its activation. Based on these findings, we speculated that high concentrations of glucocorticoid in utero led to GR in the nucleus through its activation and then inhibited the IGF1 signaling pathway by activating the glucocorticoid-activation system, which could further downregulate steroid synthesis.
Subject(s)
Adrenal Gland Diseases/chemically induced , Adrenal Glands/drug effects , Caffeine/toxicity , Central Nervous System Stimulants/toxicity , Corticosterone/metabolism , Fetal Growth Retardation/chemically induced , Hydrocortisone/metabolism , Insulin-Like Growth Factor I/metabolism , Prenatal Exposure Delayed Effects , 11-beta-Hydroxysteroid Dehydrogenases/metabolism , Adrenal Gland Diseases/metabolism , Adrenal Gland Diseases/pathology , Adrenal Glands/metabolism , Adrenal Glands/pathology , Age Factors , Animals , CCAAT-Enhancer-Binding Protein-beta/metabolism , Cell Line , Cholesterol Side-Chain Cleavage Enzyme/metabolism , Corticosterone/blood , Female , Fetal Growth Retardation/metabolism , Fetal Growth Retardation/pathology , Male , Maternal Exposure , Phosphoproteins/metabolism , Pregnancy , Rats, WistarABSTRACT
BACKGROUND/AIMS: Abuse of toluene products (e.g., glue-sniffing) primarily occurs during adolescence and has been associated with appetite suppression and weight impairments. However, the metabolic phenotype arising from adolescent inhalant abuse has never been fully characterised, and its persistence during abstinence and underlying mechanisms remain unknown. METHODS: Adolescent male Wistar rats (post-natal day 27) were exposed to inhaled toluene (10,000 ppm) (n = 32) or air (n = 48) for 1 h/day, 3 days/week for 4 weeks, followed by 4 weeks of abstinence. Twenty air rats were pair-fed to the toluene group, to differentiate the direct effects of toluene from under-nutrition. Food intake, weight, and growth were monitored. Metabolic hormones were measured after exposure and abstinence periods. Energy expenditure was measured using indirect calorimetry. Adrenal function was assessed using adrenal histology and hormone testing. RESULTS: Inhalant abuse suppressed appetite and increased energy expenditure. Reduced weight gain and growth were observed in both the toluene and pair-fed groups. Compared to the pair-fed group, and despite normalisation of food intake, the suppression of weight and growth for toluene-exposed rats persisted during abstinence. After exposure, toluene-exposed rats had low fasting blood glucose and insulin compared to the air and pair-fed groups. Consistent with adrenal insufficiency, adrenal hypertrophy and increased basal adrenocorticotropic hormone were observed in the toluene-exposed rats, despite normal basal corticosterone levels. CONCLUSIONS: Inhalant abuse results in negative energy balance, persistent growth impairment, and endocrine changes suggestive of adrenal insufficiency. We conclude that adrenal insufficiency contributes to the negative energy balance phenotype, potentially presenting a significant additional health risk for inhalant users.
Subject(s)
Adrenal Gland Diseases/chemically induced , Growth Disorders/chemically induced , Inhalant Abuse/complications , Metabolic Diseases/chemically induced , Sexual Maturation , Adolescent , Adolescent Behavior/drug effects , Adolescent Behavior/physiology , Adolescent Development/drug effects , Adrenal Gland Diseases/metabolism , Adrenal Gland Diseases/physiopathology , Adrenal Glands/physiopathology , Animals , Appetite/drug effects , Body Weight/drug effects , Disease Models, Animal , Eating/drug effects , Growth Disorders/metabolism , Growth Disorders/physiopathology , Humans , Inhalant Abuse/metabolism , Inhalant Abuse/pathology , Inhalant Abuse/physiopathology , Male , Metabolic Diseases/metabolism , Metabolic Diseases/physiopathology , Motor Activity/drug effects , Phenotype , Rats , Rats, Wistar , Sexual Maturation/drug effects , Sexual Maturation/physiology , Toluene/toxicityABSTRACT
INTRODUCTION: The potential for systemic effects due to percutaneous absorption of superpotent topical steroids has been a longstanding concern. The Food and Drug Administration currently recommends limiting the use of superpotent topical steroids to 50g per week for 2 or 4 consecutive weeks depending on the formulation, which is mostly based on the exact duration with which phase 3 clinical trials were allowed to be conducted per the FDA. This article reviews all published clinical incidence of adrenal adverse effects in the medical literature, specifically Cushing's syndrome (CS) and pathologic adrenal suppression (PAAS), to try to ascertain a more realistic limit for the safe use of superpotent topical steroids as it pertains to its potential systemic effects.
METHODS: Literature search was conducted using PubMed. Only cases of CS and PAAS secondary to the use of Class I superpotent topical steroids were included. Pediatric cases and full articles unavailable in English were excluded.
RESULTS: There were a total of 14 cases of CS and 5 cases of subsequent PAAS found in the current literature.
DISCUSSION: From our review of these cases, if the amount used per week is within FDA guidelines, it appears that patients needed to use superpotent topical steroids for far greater than 2 or 4 weeks to develop CS or PAAS. CS did not necessarily predict occurrence of PAAS, but in all cases CS appeared to be a prerequisite for developing PAAS. All cases of CS and all but one case of PAAS were reversible. If excessive amount of greater than 50g per week is avoided, it appears that superpotent topical steroids may be safe to use consecutively for months, perhaps even years, without causing systemic effects.
J Drugs Dermatol. 2017;16(7):643-648.
.Subject(s)
Adrenal Gland Diseases/chemically induced , Cushing Syndrome/chemically induced , Steroids/administration & dosage , Steroids/adverse effects , Administration, Topical , Adrenal Gland Diseases/diagnosis , Adult , Aged , Cushing Syndrome/diagnosis , Eczema/diagnosis , Eczema/drug therapy , Female , Humans , Male , Middle Aged , Psoriasis/diagnosis , Psoriasis/drug therapy , Risk FactorsABSTRACT
This is the report of a case of a 63-year-old woman, with a history of recurrent deep vein thrombosis, who was admitted with abdominal pain and diagnosed with bilateral adrenal hemorrhage, resulting in acute adrenal insufficiency. Several risk factors for adrenal hemorrhage were present: stress because of infection, treatment with the factor Xa-inhibitor rivaroxaban and the presence of antiphospholipid antibodies. Venous thrombosis of the adrenal glands with subsequent hemorrhagic infarction is a possible mechanism. It is currently unclear if patients with antiphospholipid syndrome can be treated effectively and safely with a nonvitamin K-antagonist oral anticoagulant.
Subject(s)
Adrenal Gland Diseases/chemically induced , Factor Xa Inhibitors/adverse effects , Hemorrhage/chemically induced , Rivaroxaban/adverse effects , Factor Xa Inhibitors/administration & dosage , Female , Humans , Middle Aged , Rivaroxaban/administration & dosageSubject(s)
Adrenal Gland Diseases/diagnostic imaging , Postoperative Hemorrhage/diagnostic imaging , Adrenal Gland Diseases/chemically induced , Adrenal Gland Diseases/etiology , Adrenal Gland Diseases/therapy , Aged , Anticoagulants/adverse effects , Fatal Outcome , Female , Heparin/adverse effects , Humans , Postoperative Hemorrhage/chemically induced , Postoperative Hemorrhage/therapy , Tomography, X-Ray ComputedABSTRACT
Cancer immunotherapy has introduced a novel class of drugs known as immune checkpoint inhibitors (ICIs). They enhance antitumour immunity by blocking negative regulators (checkpoints) of T cell function that exist on both immune and tumour cells. ICIs targeting CTLA-4 and PD-1/PDL-1 have dramatically changed the outcome of patients with several advanced-stage malignancies but they may lead to a variety of inflammatory toxicities and autoimmune consequences. The main endocrine immune-related adverse events (IRAEs) include hypophysitis, primary thyroid dysfunction, adrenalitis and type 1 diabetes mellitus. In general, the management of endocrine IRAEs requires assessment of their severity, in moderate or severe cases interruption of the checkpoint inhibitor and use of corticosteroid or alternative immunosuppression and appropriate hormone replacement or treatment when necessary.
Subject(s)
Adrenal Gland Diseases/chemically induced , Antineoplastic Agents, Immunological/adverse effects , B7-H1 Antigen/immunology , CTLA-4 Antigen/immunology , Diabetes Mellitus, Type 1/chemically induced , Hypophysitis/chemically induced , Immunotherapy/adverse effects , Programmed Cell Death 1 Receptor/immunology , Thyroid Diseases/chemically induced , Adrenal Gland Diseases/immunology , Diabetes Mellitus, Type 1/immunology , Humans , Hypophysitis/immunology , Thyroid Diseases/immunologyABSTRACT
We report the case of a 39-year-old man with bilateral adrenal haemorrhage. The diagnosis is rarely primarily made with imaging alone. Our patient had a previous history of a stroke six years prior to this episode. We evoke the possibility that long-term daily cannabis use could be the underlying cause of the patient's vascular pathologies. After thorough review of existing literature, this link was found to be probable. Cannabis is the most consumed recreational drug in the world, and this tendency is ever-increasing. Serious complications other than psychiatric resulting from consumption are reported with increasing frequency. Neurological, cerebrovascular, cardiovascular and respiratory complications have been observed. It is thus important to remain vigilant when patients are hospitalised notably through the emergency department, in order to obtain a complete anamnesis, optimise screening, and to adapt the treatment of these patients.